Anzeige
Mehr »
Montag, 08.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D7B9 | ISIN: US92941V3087 | Ticker-Symbol: 26JB
NASDAQ
08.09.25 | 21:25
0,295 US-Dollar
-1,11 % -0,003
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.08.VYNE Therapeutics Inc. - 8-K, Current Report2
31.07.VYNE Therapeutics stock rating downgraded to Neutral by BTIG after trial miss 10
31.07.Studienfehlschlag bei VYNE Therapeutics: BTIG senkt Rating auf 'Neutral'1
30.07.H.C. Wainwright downgrades VYNE Therapeutics stock rating on vitiligo trial data10
30.07.VYNE Therapeutics stock falls after vitiligo trial fails to meet endpoints15
VYNE THERAPEUTICS Aktie jetzt für 0€ handeln
30.07.VYNE Therapeutics Inc. - 8-K, Current Report1
30.07.VYNE Therapeutics Inc.: VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo151Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from...
► Artikel lesen
12.07.VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress1
03.07.H.C. Wainwright reiterates Buy rating on VYNE Therapeutics stock amid clinical hold update2
03.07.BTIG bekräftigt Kaufempfehlung für VYNE Therapeutics vor Vitiligo-Studiendaten3
03.07.BTIG reiterates Buy rating on VYNE Therapeutics stock ahead of vitiligo trial data2
02.07.VYNE Therapeutics Inc.: VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN2023
08.05.VYNE Therapeutics Inc. - 10-Q, Quarterly Report5
08.05.VYNE Therapeutics Inc. - 8-K, Current Report-
25.04.Pre-market Movers: Odyssey Marine Exploration, SES AI, VYNE Therapeutics, The OLB Group, Lexaria Bioscience936OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.30 A.M. ET).In the Green Odyssey Marine Exploration, Inc. (OMEX) is up over...
► Artikel lesen
25.04.VYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 Program289BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) verbally informed...
► Artikel lesen
19.02.VYNE Therapeutics Inc.: VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis219Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designed...
► Artikel lesen
06.01.VYNE Therapeutics Inc.: VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo235Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial expected in mid-2025"Repibresib" approved as the non-proprietary...
► Artikel lesen
23.12.24VYNE Therapeutics Inc.: VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor209Promising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable...
► Artikel lesen
07.11.24VYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update259VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1